Yi Chen

List of Publications by Year in descending order

60 papers	1,840 citations	279798 23 h-index	289244 40 g-index
67 all docs	67 docs citations	67 times ranked	3212 citing authors

#	Article	IF	Citations
1	SAF-248, a novel PI3KÎ´-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. Acta Pharmacologica Sinica, 2022, 43, 209-219.	6.1	3
2	Repressing MYC by targeting BET synergizes with selective inhibition of PI3KÎ± against B cell lymphoma. Cancer Letters, 2022, 524, 206-218.	7.2	9
3	The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKÎ± and overcomes gefitinib resistance in non-small cell lung cancer. Cancer Biology and Medicine, 2022, , 1-1.	3.0	2
4	Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors. European Journal of Medicinal Chemistry, 2022, 233, 114249.	5.5	5
5	Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127710.	2.2	12
6	Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. European Journal of Medicinal Chemistry, 2021, 209, 112913.	5.5	20
7	PI3KÎ± inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2021, 6, 130.	17.1	4
8	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. Acta Pharmaceutica Sinica B, 2021, 11, 1365-1378.	12.0	38
9	The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation. Molecular Cancer Therapeutics, 2021, 20, 2198-2206.	4.1	6
10	SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy. Journal of Controlled Release, 2021, 339, 297-306.	9.9	16
11	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica, 2020, 105, 1021-1031.	3.5	6
12	Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 804-815.	6.4	25
13	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer, 2020, 19, 90.	19.2	44
14	Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects. ACS Omega, 2020, 5, 350-357.	3.5	7
15	Design, Synthesis, and Biological Evaluation of HSP90 Inhibitorâ€“SN38 Conjugates for Targeted Drug Accumulation. Journal of Medicinal Chemistry, 2020, 63, 5421-5441.	6.4	11
16	TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling. Nature Communications, 2019, 10, 2863.	12.8	114
17	Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 372.	8.6	25
18	AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition. Acta Pharmacologica Sinica, 2019, 40, 1587-1595.	6.1	19

#	Article	IF	Citations
19	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro. Bioorganic and Medicinal Chemistry, 2019, 27, 1405-1413.	3.0	20
20	C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica, 2019, 40, 823-832.	6.1	18
21	Iron Metabolism in Cancer. International Journal of Molecular Sciences, 2019, 20, 95.	4.1	179
22	The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors. Molecular Cancer Therapeutics, 2019, 18, 667-679.	4.1	10
23	Molecularly precise self-assembly of theranostic nanoprobes within a single-molecular framework for in vivo tracking of tumor-specific chemotherapy. Chemical Science, 2018, 9, 4959-4969.	7.4	81
24	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2018, 148, 140-153.	5.5	12
25	Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. European Journal of Medicinal Chemistry, 2018, 145, 389-403.	5.5	40
26	Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. European Journal of Medicinal Chemistry, 2018, 152, 298-306.	5.5	8
27	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 751-762.	4.1	22
28	G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. Theranostics, 2018, 8, 2884-2895.	10.0	24
29	Discovery of JND3229 as a New EGFR^{C797S} Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Medicinal Chemistry Letters, 2018, 9, 1123-1127.	2.8	46
30	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell, 2018, 175, 186-199.e19.	28.9	166
31	Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR. European Journal of Medicinal Chemistry, 2018, 158, 428-441.	5.5	8
32	A series of camptothecin prodrugs exhibit HDAC inhibition activity. Bioorganic and Medicinal Chemistry, 2018, 26, 4706-4715.	3.0	14
33	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3KÎ±-selective inhibitor CYH33 in breast cancer. Cancer Letters, 2018, 433, 273-282.	7.2	15
34	c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Clinical Cancer Research, 2017, 23, 974-984.	7.0	27
35	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology, 2017, 65, 1948-1962.	7.3	43
36	Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. Acta Pharmacologica Sinica, 2017, 38, 1038-1047.	6.1	26

#	Article	IF	Citations
37	G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nature Communications, 2017, 8, 274.	12.8	74
38	Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Acta Pharmacologica Sinica, 2017, 38, 1533-1542.	6.1	5
39	Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced inÂvivo efficacy for cancer therapy. European Journal of Medicinal Chemistry, 2017, 138, 514-531.	5.5	18
40	Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer Letters, 2017, 386, 47-56.	7.2	45
41	Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3KÎ±-selective Inhibitors in Breast Cancer. Theranostics, 2017, 7, 974-986.	10.0	12
42	Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads. Molecules, 2017, 22, 788.	3.8	5
43	Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget, 2017, 8, 4156-4168.	1.8	31
44	10-Boronic acid substituted camptothecin as prodrug of SN-38. European Journal of Medicinal Chemistry, 2016, 116, 84-89.	5.5	51
45	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell, 2016, 30, 459-473.	16.8	117
46	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica, 2016, 37, 1481-1489.	6.1	30
47	Dual targeting of microtubule and topoisomerase II by Î±-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget, 2015, 6, 8960-8973.	1.8	35
48	Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget, 2015, 6, 2917-2927.	1.8	60
49	Design, synthesis and biological evaluation of novel homocamptothecin analogues as potent antitumor agents. Bioorganic and Medicinal Chemistry, 2015, 23, 1950-1962.	3.0	14
50	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research, 2015, 75, 4548-4559.	0.9	47
51	G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation. Acta Pharmacologica Sinica, 2014, 35, 1546-1555.	6.1	17
52	Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica, 2014, 35, 89-97.	6.1	15
53	Semisynthesis of triptolide analogues: Effect of B-ring substituents on cytotoxic activities. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5671-5674.	2.2	13
54	SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-METâ€“Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 36-45.	2.5	6

#	Article	IF	Citations
55	G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro. Acta Pharmacologica Sinica, 2014, 35, 1055-1064.	6.1	16
56	Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. ACS Medicinal Chemistry Letters, 2014, 5, 304-308.	2.8	26
57	Back Cover: Discovery of 3H-Imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation (ChemMedChem 6/2012). ChemMedChem, 2012, 7, 1129-1129.	3.2	0
58	Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition. MedChemComm, 2012, 3, 1423.	3.4	10
59	Antiangiogenic activity of 11,11â€²-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochemical and Biophysical Research Communications, 2005, 329, 1334-1342.	2.1	37
60	The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11â€²-dideoxyverticillin-induced G2/M arrest. FEBS Letters, 2005, 579, 3683-3690.	2.8	25